The drug is the second cardiac myosin inhibitor to get regulatory signoff in the United States, following mavacamten in 2022.
BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Eilean Therapeutics is a biopharmaceutical company focused on the development of best-in-class and first-in-class small molecule inhibitors that target escape mutations in hematologic malignancies and ...
MADISON, Wis.--(BUSINESS WIRE)--Research published in Science reveals a new target for non-hormonal male contraception. The protein, a kinase called STK33, has been linked to infertility in male mice ...
OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36 th EORTC-NCI-AACR (ENA) Symposium 2024 from October 23-25, in Barcelona, Spain ...
Pirtobrutinib met the primary endpoint of response rate non-inferiority, favoring pirtobrutinib with a nominal P-value for superiority < 0.05 Progression-free survival data was immature, but trending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback